Andrew Guggenhime, PRESIDENT AND CFO at Vaxcyte, Inc. (PCVX), sold 15,660 shares at $74.08 ($1.2M) on 2024-02-20, disclosed to the SEC on 2024-02-22.
Scheduled sale ($1.2M) by PRESIDENT AND CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $74.08 | 4,909 | $364K | 31.2% |
| 2 | $74.08 | 4,909 | $364K | 31.2% |
| 3 | $75.17 | 2,751 | $207K | 17.7% |
| 4 | $75.17 | 2,751 | $207K | 17.7% |
| 5 | $75.80 | 340 | $26K | 2.2% |
| Total | $74.50 avg | 15,660 |
| $1.2M |
| 100% |
| Filing → |
| PCVX | SELL | 2026-06-18 | $530K | — | Filing → |
| PCVX | SELL | 2025-02-19 | $1.3M | — | Filing → |
| PCVX | SELL | 2025-01-22 | $1.4M | — | Filing → |